Biomarker ID | 852 |
PMID | 22298030 |
Year | 2012 |
Biomarker | miR-25 |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Plasma |
Subjects | Humans |
Regulation | Downregulated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:- DNA-binding transcription factor activity, RNA polymerase II-specific; DNA-binding transcription factor activity; nuclear chromatin; chromatin; nuclear chromosome |
Experiment | prostate cancer Vs benign prostatic hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | Training set: 25 patients with prostate cancer, 17 with Benign prostatic hyperplasia. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | Training: p<0.0001; Not significant in validation set |
Method Used | Training Set: Microarrays, Validation set; qRT-PCR |
Clinical | No |
Remarks | Not significant in Validation set |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Independent Patient Cohort |
Technical Name | miR-25 |